Clingenix, Inc. was founded in 1998 by leading scientists from Harvard, Stanford, and private industry to provide pharmacogenomic as well as conventional research, development and application services to the drug development and medical device industries. The founders are experts in the fields of medicine, genetics, clinical trials, and information technology. The Company is headquartered in Sunnyvale, California with operations through out the US, Taiwan and the Asia Pacific Region. The company provides a full range of services from developmental consulting, through all phases of clinical development, to commercialization.
The mission of the Company is to be the premiere pharmacogenomics company offering a full range of genomic based research, development and application services and diagnostic products for monitoring diseases and disease progression to pharmaceutical, biotechnology, medical device, and diagnostic companies for drug development and commercialization.
Clingenix provides pharmacogenomics services and diagnostic products in the therapeutic areas of diabetes, insulin resistance, hypertension, oncology, cardiovascular and atherosclerosis. The company is currently expanding to other therapeutic areas using the initial template.
Clingenix's management believes that the application of pharmacogenomics knowledge coupled with traditional discovery and developmental processes to drug development will reduce clinical trial costs, shorten the drug development cycle, improve new drugs approval rate and market positioning, rescue drugs that will or have failed clinical trial or FDA approval, and improve trial predictability. These outcomes are possible because
pharmacogenomics allows for better targeting, higher efficacy, and lower toxicity of new drugs.
The Company services provide for many commercial advantages in medicine, and diagnostics. Clingenix enjoys a decisive market advantage over its competitors through existing capabilities in Asia. Advantages include extensive access to investigators and patients, ownership of biological materials from type 2 diabetes, ownership of a database in the insulin resistant and hypertension therapeutic areas, and world renown technical expertise in these therapeutic areas. The database contains genotype, phenotype, and metabolic data, total genome scan with over 300 markers, and immortal cell lines. Putative loci linked to resistance and dyslipidemia have also been identified.
Clingenix collaborates with academic and industrial leaders in pharmaceuticals, diagnostics, biotechnology, and medical instrumentation.
Based on a strong foundation in medicine, genomics, clinical trials, and information technology, Clingenix promises to be the premiere provider of pharmacogenomics services and products.
| Contact Details: |
| 1190 Bordeaux Drive |
| Sunnyvale |
| CA |
| 94089 |
| United States of America |
| Tel: | (408) 752-1635 |
| Fax: | (408) 752-0347 |
| Email: | dgessner@clingenix.com |
| WWW: | www.clingenix.com/
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 455 times since April 2007, the link to the organisation's website has been followed 110 times
Recent Search Terms used to find this page: t | Clingenix | clingenix | t | t | Clingenix Inc. of USA | clingenix sunnyvale california | Clingenix | CLINGENIX | pharmacogenomics drugs approval | .
Search for more companies in Sunnyvale
Search for more companies in CA
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Clingenix Incorporated
